La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale

Translated title of the contribution: Subcutaneous insulin infusion (CSII) in italy: The third nationa survey

D. Bruttomesso, L. Laviola, G. Lepore, R. Bonfanti, L. Bozzetto, A. Corsi, V. Di Blasi, A. Girelli, G. Grassi, D. Iafusco, I. Rabbone, R. Schiaffini, V. Montani, P. Colleluori, V. Paciotti, P. Alfidi, J. Grosso, S. Tumini, P. Cipriano, E. VitacolonnaG. Di Vieste, A. Minnucci, D. Antenucci, G. La Penna, M. Taraborrelli, B. Macerala, G. Citro, G. De Morelli, A. Gnasso, C. Irace, F. Citriniti, N. Lazzaro, M. Bruzzese, F. Mammì, F. De Berardinis, E. Santoro, G. Tornese, E. Faleschini, A. Crinò, M. Cappa, D. Maggi, N. Minuto, V. Fuso, E. Orsi, A. Laurenzi, G. Torchio, E. Cazzaniga, R. A. Rabini, S. Giovanni, A. Rauseo, La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo

Research output: Contribution to journalArticle

Abstract

Continuous subcutaneous insulin infusion (CSII) is increasingly being used worldwide, mostly thanks to technical improvements. This study examined the current status of CSII in Italy. Physicians in charge of 272 diabetes centers caring for patients using CSII were sent a questionnaire investigating clinical features, pump technology and management of these patients; a large proportion (217 centers, 79.8%) joined the study. By end-April 2013, data had been collected on 10152 patients treated with CSII; 98.2% had type 1 diabetes, 82.4% were adults, 57% female. Only just over half the centers (59%) managed more than 20 CSII patients each. The distribution of patients varied widely both among and within different regions. The main indication for CSII was the de- sire to improve glycemic control. Dropouts (8.65%) were mainly due to difficulties with pump wearability or non-optimal glycemic control. Among CSII patients 61% used a traditional pump, 39% a sensor augmented pump. Only 68% used the CSII advanced functions and glucose sensors were used twelve days per month on average. Round-the-clock assistance was guaranteed in 81% of centers; a full diabetes team followed patients in only 40% of adult-care centers and 50% of pediatric units. CSII is increasingly used in Italy, by adults and pediatric patients. However, further work is needed to unify treatment strategies throughout the country and to encourage optimal pump use and applications.

Original languageItalian
Pages (from-to)121-129
Number of pages9
JournalGiornale Italiano di Diabetologia e Metabolismo
Volume35
Issue number2
Publication statusPublished - Jun 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bruttomesso, D., Laviola, L., Lepore, G., Bonfanti, R., Bozzetto, L., Corsi, A., Di Blasi, V., Girelli, A., Grassi, G., Iafusco, D., Rabbone, I., Schiaffini, R., Montani, V., Colleluori, P., Paciotti, V., Alfidi, P., Grosso, J., Tumini, S., Cipriano, P., ... La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo (2015). La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale. Giornale Italiano di Diabetologia e Metabolismo, 35(2), 121-129.